Anton K. Peresada, D. Dundua, A. Kedrova, Irina N. Oleinikova, Anna V. Masterkova
{"title":"A modern view on cardioprotective therapy in cancer patients receiving cardiotoxic chemotherapy","authors":"Anton K. Peresada, D. Dundua, A. Kedrova, Irina N. Oleinikova, Anna V. Masterkova","doi":"10.17816/clinpract567924","DOIUrl":null,"url":null,"abstract":"Background: Cancer patients receiving high doses of cardiotoxic combined anticancer drugs have an increased risk of cardiovascular complications. During treatment, patients may experience complications from the cardiovascular system, in particular chronic heart failure (CHF). Without the necessary laboratory and instrumental control, it is impossible to predict in advance the development of heart failure, which often complicates chemotherapy, and, in some cases necessitates cancellation of life-saving anticancer therapy. It turned out that timely cardioprotection, a drug intervention aimed at preventing myocardial dysfunction in cancer patients, can prevent the development of heart failure. Aim: The purpose of this review is to briefly reflect the mechanisms of cardiotoxicity in various chemotherapy regimens, as well as the current possibilities of cardioprotection in cancer patients receiving cardiotoxic chemotherapy","PeriodicalId":508133,"journal":{"name":"Journal of Clinical Practice","volume":"2 1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17816/clinpract567924","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Cancer patients receiving high doses of cardiotoxic combined anticancer drugs have an increased risk of cardiovascular complications. During treatment, patients may experience complications from the cardiovascular system, in particular chronic heart failure (CHF). Without the necessary laboratory and instrumental control, it is impossible to predict in advance the development of heart failure, which often complicates chemotherapy, and, in some cases necessitates cancellation of life-saving anticancer therapy. It turned out that timely cardioprotection, a drug intervention aimed at preventing myocardial dysfunction in cancer patients, can prevent the development of heart failure. Aim: The purpose of this review is to briefly reflect the mechanisms of cardiotoxicity in various chemotherapy regimens, as well as the current possibilities of cardioprotection in cancer patients receiving cardiotoxic chemotherapy
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
